PMID: 9554680Apr 29, 1998Paper

Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group

Archives of Internal Medicine
P J SavageJ Stamler

Abstract

Previous studies often of short duration have raised concerns that antihypertensive therapy with diuretics and beta-blockers adversely alters levels of other cardiovascular disease risk factors. The Systolic Hypertension in the Elderly Program was a community-based, multicenter, randomized, double-blind, placebo-controlled clinical trial of treatment of isolated systolic hypertension in men and women aged 60 years and older. This retrospective analysis evaluated development of diabetes mellitus in all 4736 participants in the Systolic Hypertension in the Elderly Program, including changes in serum chemistry test results in a subgroup for 3 years. Patients were randomized to receive placebo or treatment with active drugs, with the dose increased in stepwise fashion if blood pressure control goals were not attained: step 1, 12.5 mg of chlorthalidone or 25.0 mg of chlorthalidone; and step 2, the addition of 25 mg of atenolol or 50 mg of atenolol or reserpine or matching placebo. After 3 years, the active treatment group had a 13/4 mm Hg greater reduction in systolic and diastolic blood pressure than the placebo group (both groups, P<.001). New cases of diabetes were reported by 8.6% of the participants in the active treatment grou...Continue Reading

Associated Clinical Trials

Citations

Dec 18, 2013·Current Hypertension Reports·Joshua I BarzilayPaul K Whelton
Dec 6, 2007·Journal of General Internal Medicine·Monika M SaffordCatarina I Kiefe
Mar 6, 2008·Internal and Emergency Medicine·Takahiko NakagawaRichard J Johnson
Aug 13, 2008·Current Opinion in Nephrology and Hypertension·Sirirat ReungjuiTakahiko Nakagawa
Nov 5, 2008·Hypertension·Tariq ShafiRulan S Parekh
May 30, 2009·Vascular Health and Risk Management·Amber LundyCherylyn Beckey
Oct 21, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroshi ItoUNKNOWN Effect of ARB/Diuretics on Diastolic Function in Patients with Hypertension (EDEN) trial investigators
Jul 2, 2002·The American Journal of Geriatric Cardiology·G E Sander
Jul 30, 2002·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Ihab HajjarVictor Hirth
Sep 17, 2009·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Knud Landmark, Asmund Reikvam
Aug 3, 2005·Current Hypertension Reports·Tonje Amb AksnesGiuseppe Mancia
Sep 12, 2000·Current Hypertension Reports·R D Brook
Nov 6, 2004·Current Hypertension Reports·Gary E Sander
Jul 8, 2003·Current Hypertension Reports·Luis M Ruilope
Jul 8, 2003·Current Hypertension Reports·Bernard Waeber
Jul 31, 2012·Current Hypertension Reports·Ji-Guang Wang, Yan Li
Jul 11, 2013·Current Hypertension Reports·George C RoushTheodore R Holford
Oct 28, 2008·Journal of Postgraduate Medicine·Ahh DamanhoriR P Sequeira
Oct 16, 2003·Current Cardiology Reports·Bernard Waeber
Oct 6, 2011·Current Cardiology Reports·Gary E Sander, Thomas D Giles
Aug 13, 2003·Current Atherosclerosis Reports·Richard J MacIsaac, Mark E Cooper
Feb 25, 2005·Current Atherosclerosis Reports·John B Standridge
Jul 18, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Li-Tao ChengTao Wang
Mar 30, 2000·The New England Journal of Medicine·J R Sowers, G L Bakris
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Marion R Wofford, Deborah S King
Mar 29, 2008·Metabolic Syndrome and Related Disorders·David Siegel, Arthur L M Swislocki
Feb 17, 2010·Metabolic Syndrome and Related Disorders·David Siegel, Arthur L M Swislocki
Jun 10, 2010·Expert Review of Cardiovascular Therapy·Julio D Duarte, Rhonda M Cooper-DeHoff
Nov 1, 2005·Expert Opinion on Drug Safety·Hassane IzzedineGilbert Deray
Oct 30, 2013·Clinical and Experimental Hypertension : CHE·Ryuichi KawamotoTetsuro Miki
Nov 27, 2009·The New England Journal of Medicine·Michael E Ernst, Marvin Moser
Oct 12, 2007·Kidney International·S ReungjuiR J Johnson
Jun 27, 2003·The Journal of Clinical Hypertension·George L BakrisUNKNOWN Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators
Dec 28, 2004·The American Journal of Cardiology·John B KostisUNKNOWN SHEP Collaborative Research Group
Sep 16, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Neila FathallahChaker Ben Salem
Sep 1, 1999·Rheumatic Diseases Clinics of North America·C M Chou
May 24, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshiyuki KudohIzumi Nakagawa
Oct 2, 2012·Expert Opinion on Therapeutic Targets·Andréa Name Colado SimãoIsaias Dichi
Jan 22, 2014·Expert Opinion on Pharmacotherapy·Juan TamargoLuis M Ruilope

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

International Journal of Hypertension
Wenwen Zhang, Ninghua Li
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Hiroshi NotoMitsuhiko Noda
Circulation. Cardiovascular Quality and Outcomes
Ranee R Lleva, Silvio E Inzucchi
© 2022 Meta ULC. All rights reserved